Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
3.7
Journals
Metabolites
Special Issues
Research on Biomarkers for Cardiometabolic Risk in Metabolic Syndrome—2nd Edition
share announcement

Research on Biomarkers for Cardiometabolic Risk in Metabolic Syndrome—2nd Edition

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: 15 December 2026 | Viewed by 1223

Special Issue Editors

Dr. Antoaneta Trifonova Gateva

E-Mail Website
Guest Editor
Department of Internal Medicine, Aleksandrovska University Hospital, Medical University of Sofia, 1431 Sofia, Bulgaria
Interests: prediabetes; metabolic syndrome; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Yavor Sashov Assyov

E-Mail Website
Guest Editor
Department of Internal Medicine, Aleksandrovska University Hospital, Medical University of Sofia, 1431 Sofia, Bulgaria
Interests: metabolic syndrome; sarcopenia; myokines; diabetes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metabolic syndrome (MS) is a complex of specific risk factors related to the development of cardiovascular diseases and diabetes mellitus type 2. The definition of MS includes abdominal obesity, insulin resistance, dyslipidemia, and elevated blood pressure. They are associated with various other disturbances such as prothrombotic condition, chronic low-grade inflammation, non-alcoholic liver steatosis, obstructive sleep apnea, reproductive disorders, etc. The distribution of metabolic syndrome has been increasing in the last 20 years. It turned into an epidemic in developed and developing countries, making it a medical problem with a growing importance of social impact.

A comprehensive approach that influences the main components of MS is essential, especially in high-risk patients, to normalize the primary metabolic abnormalities, which will reduce the cardiovascular risk and the risk of DM2 in the long term. Recently, increasing attention has been directed to personalized medicine and individualized approaches, not only in relation to therapeutics but also to preventive interventions aimed at influencing risk factors and reducing long-term complications. The personalized approach is based on the individual characteristics of patients, including different biomarkers and genetic variants. This Special Issue aims to collect research articles and reviews exploring biomarkers associated with cardiometabolic risk in individuals with metabolic syndrome, with a particular focus on identifying novel markers and elucidating their role in disease pathogenesis and prevention.

We look forward to receiving your contributions.

Dr. Antoaneta Trifonova Gateva
Dr. Yavor Sashov Assyov
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic syndrome
  • vascular complications
  • biomarkers
  • carbohydrate disturbances
  • diabetes
  • pre-diabetes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 799 KB  
Article
Metabolomic Signature of Visceral Adiposity: Insights from a Population-Based Cohort
by Khaled Naja, Najeha Anwardeen, Shamma Almuraikhy, Mohamed A. Elrayess and Ahmed Malki
Metabolites 2026, 16(5), 343; https://doi.org/10.3390/metabo16050343 - 19 May 2026
Viewed by 141
Abstract
Background: Visceral adipose tissue (VAT) is a key determinant of cardiometabolic risk, yet its underlying molecular mechanisms remain incompletely characterized. Metabolomics offers an opportunity to identify circulating biomarkers that capture VAT-related biology beyond conventional clinical measures. Methods: We conducted a cross-sectional analysis [...] Read more.
Background: Visceral adipose tissue (VAT) is a key determinant of cardiometabolic risk, yet its underlying molecular mechanisms remain incompletely characterized. Metabolomics offers an opportunity to identify circulating biomarkers that capture VAT-related biology beyond conventional clinical measures. Methods: We conducted a cross-sectional analysis of 2526 participants from the Qatar Biobank using untargeted serum metabolomics profiling. VAT was quantified using DXA-derived estimates and analyzed both as a continuous variable and by comparing individuals in the highest quartile to the remainder quartiles. Associations between metabolites and VAT were assessed using multivariate partial least squares discriminant analysis and adjusted linear regression models controlling for age, sex, and BMI, with Bonferroni correction for multiple testing. Results: Continuous VAT was associated with 106 metabolites, while the Q4 versus Q1–Q3 contrast identified 23 metabolites, with overlapping metabolites defining a robust core VAT signature. Higher VAT was characterized by coordinated elevation of branched-chain amino acids and their keto/hydroxy acid derivatives, glutamate, and central carbon intermediates, consistent with impaired mitochondrial oxidative decarboxylation. We further identified 4-hydroxyglutamate as a novel collagen-derived metabolite positively associated with VAT, suggesting a potential link between extracellular matrix remodeling and glutamate-centered metabolism. Additionally, greater VAT was associated with lower concentrations of glycine and glycine conjugates and reduced levels of unsaturated sphingomyelins and plasmalogens. Conclusions: These findings provide potential mechanistic insights into VAT-related metabolic dysfunction and identify candidate circulating biomarkers that may enable non-invasive assessment of visceral fat-associated cardiometabolic risk. Longitudinal and mechanistic studies are warranted to establish causality and clinical utility. Full article
(This article belongs to the Special Issue Research on Biomarkers for Cardiometabolic Risk in Metabolic Syndrome—2nd Edition)
►▼ Show Figures

Figure 1

13 pages, 921 KB  
Article
Expression of miR-210-3p as a Prognostic Marker for Development of Diabetic Neuropathy
by Savelia G. Yordanova, Diana Nikolova, Zdravko Kamenov, Vera Karamfilova, Traykov Lachezar, Yavor Assyov, Tsvetan Gatev, Radka Kaneva, Olga Belcheva, Darina Kachakova, Veronika Petkova, Yavor Zhelev and Antoaneta Trifonova Gateva
Metabolites 2026, 16(1), 13; https://doi.org/10.3390/metabo16010013 - 23 Dec 2025
Viewed by 794
Abstract
Background/Objectives: Diabetic neuropathy (DN) is one of the most common complications of type 2 diabetes mellitus (T2DM), involving complex metabolic, vascular, and epigenetic mechanisms. MicroRNA-210-3p (miR-210-3p), a hypoxia-responsive molecule, has been implicated in various diabetic complications, but its role in DN is [...] Read more.
Background/Objectives: Diabetic neuropathy (DN) is one of the most common complications of type 2 diabetes mellitus (T2DM), involving complex metabolic, vascular, and epigenetic mechanisms. MicroRNA-210-3p (miR-210-3p), a hypoxia-responsive molecule, has been implicated in various diabetic complications, but its role in DN is not well defined. This study aimed to investigate the relationship between miR-210-3p expression, measured as delta Ct (ΔCt), and the presence and type of diabetic neuropathy, as well as correlations with corneal nerve parameters assessed by corneal confocal microscopy (CCM). Methods: Eighty patients with T2DM were stratified into four groups: no neuropathy, autonomic neuropathy, peripheral neuropathy, and combined neuropathy. Expression of miR-210-3p was quantified using RT-qPCR, and CCM was used to measure corneal nerve fiber density (CNFD), length (CNFL), and branch density (CNBD). Results: ΔCt values were significantly lower in patients with combined neuropathy compared to those without neuropathy, indicating higher miR-210-3p expression. Intermediate values were observed in autonomic and peripheral neuropathy groups. CCM parameters were significantly reduced in patients with DN. ΔCt was inversely correlated with neuropathy severity but positively associated with diabetes duration. Conclusions: These findings suggest that miR-210-3p may serve as a biomarker of nerve damage and cellular stress in diabetes, and that combining gene expression profiling with CCM could improve DN diagnosis and monitoring. Full article
(This article belongs to the Special Issue Research on Biomarkers for Cardiometabolic Risk in Metabolic Syndrome—2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop